Therapeutic Challenges in Metastatic Non-small Cell Lung Cancer (NSCLC) With Concurrent Mesenchymal-Epithelial Transition Factor (MET) Amplification and High Programmed Death-Ligand 1 (PD-L1) Expression: A Case Study. (PubMed, Cureus) - Sep 29, 2026 - "Because the CGP and PD-L1 results returned only after treatment had started, first-line platinum-doublet chemotherapy (nab-paclitaxel/carboplatin) was given, with a mixed response and a new hepatic metastasis. Second-line atezolizumab plus pemetrexed/carboplatin produced a partial response, followed by brain metastases...Notably, a marked response to capmatinib occurred despite an intermediate MET copy number below the threshold usually associated with benefit. Any role for combined or sequential MET inhibition and immunotherapy remains a hypothesis requiring prospective study rather than a conclusion supported by this single case, and cross-assay PD-L1 results should be interpreted with caution."
IO biomarker • Journal • Hepatocellular Cancer • Hepatology • Infectious Disease • Liver Failure • Lung Adenocarcinoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Otorhinolaryngology • Septic Shock • Solid Tumor • MET • PD-L1 • TP53
|
|
Arman Reza Chowdhury; Hasin Mesbah Bin Siddique; Masud Parvez; Md Arifur Rahman; Mohammad S Faisal
|